C. diff Risk


Oral Bioavailability

Excellent (90 to 100%)

Approximate Cost

$0.30 (PO)
$81.87 (IV)


500-750mg PO/IV daily

General Information

Common Usage

  • Lower respiratory infection (CAP, HAP)

  • Intraabdominal infection (with metronidazole)

Drug Monitoring

Monitor QTc in patients with increased risk

Adverse Effects

  • QTc prolongation

  • Dysglycemia

  • Rash

  • Tendinopathy and rupture

  • GI upset

  • Weakness exacerbation in myasthenia gravis

  • CNS toxicity including confusion, psychosis

Major Interactions

  • Other QTc prolonging agents

  • Divalent cations - Decreased absorption

  • NSAIDs - Increase seizure risk

  • Warfarin - Increased INR

Tablet/Capsule Strengths

Special Authorization Required

Additional Information

IV Administration
Premixed bags; infusion time 250 mg (30 min), 500 mg (60 min), 750 mg (90 min)

EH Prescribing Restrictions
None (Pharmacist reviews IV therapy)

NLPDP Status (PO)
Special Authorization required

Community IV Formulary (Metro Area)
NO. Premixed bags are not compatible with pumps used by community IV program


Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 7 hours

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Biliary penetration: Therapeutic